ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Clinical trial NCT07109531 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07109531
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-31
- Primary completion
- 2027-10-31
- Enrollment
- 286
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.